Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 7/20 | 0.40 |
| ▸ | RXRB | P28702 | 6/20 | 0.40 |
| ▸ | RXRG | P48443 | 5/20 | 0.40 |
| ▸ | GRM5 | P41594 | 2/20 | 0.38 |
| ▸ | SYK | P43405 | 1/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.37 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | MAP3K8 | P41279 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5097591 | 0.82 | RXRA (0.53) | RXRARXRBRXRGMEN1KMT2A | |
| SCHEMBL3553376 | 0.80 | GRM5 (0.40) | GRM5CHRNB2CHRNA4KCNA5DYRK1A | |
| SCHEMBL3554873 | 0.76 | EPHB4 (0.43) | MEN1KMT2A | |
| SCHEMBL3409401 | 0.74 | KCNA5 (0.49) | GRM5CHRNB2CHRNA4KCNA5 | |
| Hydrochloric Acid SCHEMBL4024971 | 0.72 | KCNA5 (0.47) | GRM5CHRNB2CHRNA4KCNA5 | |
| SCHEMBL3560362 | 0.72 | CYP2D6 (0.40) | RXRARXRBRXRGMEN1KMT2A | |
| SCHEMBL13367575 | 0.70 | KCNA5 (0.41) | GRM5CHRNB2CHRNA4KCNA5 | |
| SCHEMBL2128199 | 0.70 | CYP2A6 (0.47) | GRM5SYKCHRNB2CHRNA4KCNA5 | |
| SCHEMBL23577438 | 0.70 | EGFR (0.60) | MEN1KMT2A | |
| SCHEMBL30013867 | 0.70 | EGFR (0.60) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7696204-B2 | Pharmaceutical compounds | LUDWIG INSTITUTE FOR CANCER RESEARCH (CH) | 2010-04-13 | — | — | US | disclosed |
| US-20090156601-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-18 | — | — | US | disclosed |
| US-20090042884-A1 | Pharmaceutical Compounds | F.HOFFMANN-LA ROCHE AG (CH) | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042884-A1 | Pharmaceutical Compounds | PIK3CA, JAK1, PIK3R1 | RXRA 1143/4885RXRB 986/4885RXRG 942/4885 |
| US-20090156601-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF CANCER | NR3C1, NR4A3, NR4A1 | RXRA 166/4885RXRB 99/4885RXRG 171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.